Intensity Modulated Radiation Therapy Plus Etoposide/Cisplatin for Patients With Limited Advanced Unresectable Thymic Epithelial Tumors: A Prospective Phase 2 Study

医学 白细胞减少症 依托泊苷 内科学 临床研究阶段 放射治疗 临床终点 胃肠病学 不利影响 前瞻性队列研究 存活率 肿瘤科 化疗 临床试验
作者
Xing-Wen Fan,Yu Yang,Hong-Bing Wang,Yin Xu,Mei Kang,Li-Yi Xie,Ling Li,Wentao Fang,Kuaile Zhao,Haiquan Chen,Jia-Qing Xiang,Yee Ung,Chong Shun Wong,Guo-Liang Jiang,Kailiang Wu
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:107 (1): 98-105 被引量:26
标识
DOI:10.1016/j.ijrobp.2019.12.045
摘要

PURPOSE: This prospective phase 2 study evaluated the efficacy and safety of intensity modulated radiation therapy plus etoposide/cisplatin (EP) for patients with unresectable thymic epithelial tumors (TETs). METHODS AND MATERIALS: cisplatin on days 1-3 and days 29-31) were administered concurrently with radiation therapy, followed by 2 cycles after radiation therapy. The primary endpoint was the objective response rate. The secondary endpoints were the progression-free survival rate, overall survival rate, and incidence of adverse events. RESULTS: Fifty-six patients were enrolled between June 2011 and May 2018. Twenty-two and 34 patients had thymomas and thymic carcinomas, respectively. The median age was 52 (range, 21-76) years, and 30 patients (53.6%) were men. Eight patients (14.3%) had stage III tumors, 6 (10.7%) had stage IVA tumors, and 42 (75.0%) had stage IVB tumors. The objective response rate was 85.7% (95% confidence interval, 76.3%-95.2%). With a median follow-up of 46 (range, 7-101) months, the 1-, 2-, and 5-year progression-free survival rates were 66.1%, 48.0%, and 29.5%, and the 1-, 2-, and 5-year overall survival rates were 91.0%, 76.2%, and 56.2%, respectively. The most common grade 3 to 4 adverse event was leukopenia (42.9%). Pulmonary fibrosis was also observed (5.3%). CONCLUSIONS: Because intensity modulated radiation therapy with EP is effective and safe for limited advanced unresectable TETs, it could be a suitable treatment option for such patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
pluto的应助被xzn1123采纳,获得20
1秒前
hhh完成签到,获得积分10
2秒前
hu完成签到,获得积分10
2秒前
苗条平萱完成签到,获得积分10
2秒前
阿梨完成签到 ,获得积分10
2秒前
123完成签到,获得积分10
2秒前
2秒前
明白放弃完成签到,获得积分10
2秒前
Chloe完成签到 ,获得积分10
3秒前
jljyboki完成签到,获得积分10
3秒前
qu蛐完成签到 ,获得积分10
3秒前
luoshikun完成签到,获得积分10
3秒前
风景的谷建芬完成签到,获得积分10
3秒前
路明非完成签到,获得积分10
4秒前
4秒前
Kay76完成签到,获得积分10
4秒前
活力的白桃完成签到,获得积分10
4秒前
优雅的采波完成签到,获得积分20
6秒前
6秒前
大力的含卉完成签到,获得积分10
6秒前
义气千风完成签到,获得积分10
7秒前
我要出去玩完成签到,获得积分10
7秒前
yh完成签到,获得积分10
8秒前
thinking完成签到,获得积分10
9秒前
火星上的铃铛完成签到,获得积分10
9秒前
Ie完成签到,获得积分10
9秒前
Hj完成签到 ,获得积分20
10秒前
白元正完成签到,获得积分10
10秒前
ao黛雷赫完成签到,获得积分10
10秒前
馥芮白完成签到,获得积分10
11秒前
从容的香彤完成签到,获得积分10
12秒前
钱塘郎中完成签到,获得积分0
12秒前
Neoshine完成签到,获得积分10
13秒前
爆米花的应助被Lucifer采纳,获得10
13秒前
xol完成签到 ,获得积分10
13秒前
海底的星河完成签到,获得积分10
13秒前
liu完成签到,获得积分10
13秒前
Jinoral完成签到,获得积分10
13秒前
娜就酱紫霸完成签到 ,获得积分10
14秒前
宋北山完成签到 ,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173463
求助须知:如何正确求助?哪些是违规求助? 9565690
关于积分的说明 21781315
捐赠科研通 7767647
什么是DOI,文献DOI怎么找? 3431597
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476808